Availability for Non-Exclusive or Partially Exclusive Licensing of a U.S. Patent Application, 39667 [2010-16894]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 132 / Monday, July 12, 2010 / Notices
is also available on the CPSC Web site
at https://www.cpsc.gov.
DEPARTMENT OF DEFENSE
Dated: July 6, 2010.
Todd A. Stevenson,
Secretary, Consumer Product Safety
Commission.
Department of the Army
Availability for Non-Exclusive or
Partially Exclusive Licensing of a U.S.
Patent Application
[FR Doc. 2010–16918 Filed 7–9–10; 8:45 am]
ACTION:
DEPARTMENT OF DEFENSE
Department of the Army
Availability for Non-Exclusive or
Partially Exclusive Licensing of a U.S.
Patent Application
Department of the Army, DoD.
Notice.
AGENCY:
ACTION:
erowe on DSK5CLS3C1PROD with NOTICES
SUMMARY: Announcement is made of the
availability for licensing of the
invention set forth in U.S. Patent
7,632,659, which issued on December
15, 2009, entitled ‘‘Use of Shigella
Invaplex to Transport Functional
Proteins and Transcriptionally Active
Nucleic Acids Across Mammalian Cell
Membranes In Vitro and In Vivo,’’ and
U.S. Patent Application Serial No. 12/
563,794, entitled ‘‘Use of Shigella
Invaplex to Transport Functional
Proteins and Transcriptionally Active
Nucleic Acids Across Mammalian Cell
Membranes In Vitro and In Vivo,’’ filed
September 21, 2009. U.S. Patent
Application Serial No. 12/563,794 is a
continuation application of U.S. Patent
7,632,659. Foreign rights are also
available for licensing (PCT/US2004/
039100). The United States Government,
as represented by the Secretary of the
Army, has rights to this invention.
ADDRESSES: Commander, U.S. Army
Medical Research and Materiel
Command, ATTN: Command Judge
Advocate, MCMR–JA, 504 Scott Street,
Fort Detrick, Frederick, MD 21702–
5012.
FOR FURTHER INFORMATION CONTACT: For
patent issues, Ms. Elizabeth Arwine,
Patent Attorney, (301) 619–7808. For
licensing issues, Dr. Paul Mele, Office of
Research and Technology Applications
(ORTA), (301) 619–6664, both at telefax
(301) 619–5034.
SUPPLEMENTARY INFORMATION: The
inventions relate to the use of Invaplex
to transport materials, including
functional proteins and biologically
active nucleic acids, across eukaryotic
cell membranes.
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2010–16889 Filed 7–9–10; 8:45 am]
BILLING CODE 3710–08–P
VerDate Mar<15>2010
14:19 Jul 09, 2010
Department of the Army, DoD.
Notice.
AGENCY:
BILLING CODE 6355–01–P
Jkt 220001
SUMMARY: Announcement is made of the
availability for licensing of the
invention set forth in U.S. Patent
Application Serial No. 11/727,486,
entitled ‘‘Artificial Invaplex,’’ filed
March 27, 2007. Foreign rights are also
available for licensing (PCT/US2007/
007482). The United States Government,
as represented by the Secretary of the
Army, has rights to this invention.
ADDRESSES: Commander, U.S. Army
Medical Research and Materiel
Command, ATTN: Command Judge
Advocate, MCMR–JA, 504 Scott Street,
Fort Detrick, Frederick, MD 21702–
5012.
FOR FURTHER INFORMATION CONTACT: For
patent issues, Ms. Elizabeth Arwine,
Patent Attorney, (301) 619–7808. For
licensing issues, Dr. Paul Mele, Office of
Research and Technology Applications
(ORTA), (301) 619–6664, both at telefax
(301) 619–5034.
SUPPLEMENTARY INFORMATION: The
invention relates to an artificial invasin
complex hat can facilitate the transport
of biomolecules, therapeutics and
antibiotics across cell membranes in a
manner similar to native Shigella
Invaplex.
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2010–16897 Filed 7–9–10; 8:45 am]
BILLING CODE 3710–08–P
DEPARTMENT OF DEFENSE
Department of the Army
Availability for Non-Exclusive or
Partially Exclusive Licensing of a U.S.
Patent Application
Department of the Army, DoD.
Notice.
AGENCY:
ACTION:
Announcement is made of the
availability for licensing of the
invention set forth in U.S. Patent
Application Serial No. 12/149,076,
entitled ‘‘Combinations of Gene
Deletions for Live Attenuated Shigella
Vaccine Strains,’’ filed April 25, 2008.
Foreign rights are also available for
licensing (PCT/US2008/005342). The
United States Government, as
SUMMARY:
PO 00000
Frm 00016
Fmt 4703
Sfmt 4703
39667
represented by the Secretary of the
Army, has rights to this invention.
ADDRESSES: Commander, U.S. Army
Medical Research and Materiel
Command, ATTN: Command Judge
Advocate, MCMR–JA, 504 Scott Street,
Fort Detrick, Frederick, MD 21702–
5012.
FOR FURTHER INFORMATION CONTACT: For
patent issues, Ms. Elizabeth Arwine,
Patent Attorney, (301) 619–7808. For
licensing issues, Dr. Paul Mele, Office of
Research and Technology Applications
(ORTA), (301) 619–6664, both at telefax
(301) 619–5034.
SUPPLEMENTARY INFORMATION: The
invention relates generally to Shigella
vaccine, strains, their use in vaccines,
and the methods for treatment of
dysentery.
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2010–16894 Filed 7–9–10; 8:45 am]
BILLING CODE 3710–08–P
DEPARTMENT OF DEFENSE
Department of the Army
Availability for Non-Exclusive or
Partially Exclusive Licensing of a U.S.
Patent Application
Department of the Army, DoD.
Notice.
AGENCY:
ACTION:
SUMMARY: Announcement is made of the
availability for licensing of the
invention set forth in U.S. Patent
Application Serial No. 11/132,199,
entitled ‘‘Construction of Live
Attenuated Shigella Vaccine Strains that
Express CFA/I Antigens (CFAB and
CFAE) and the B Subunit of Heat-Labile
Enterotoxin (LTB) From Enterotoxigenic
E. Coli,’’ filed May 19, 2005. The United
States Government, as represented by
the Secretary of the Army, has rights to
this invention.
ADDRESSES: Commander, U.S. Army
Medical Research and Materiel
Command, ATTN: Command Judge
Advocate, MCMR–JA, 504 Scott Street,
Fort Detrick, Frederick, MD 21702–
5012.
FOR FURTHER INFORMATION CONTACT: For
patent issues, Ms. Elizabeth Arwine,
Patent Attorney, (301) 619–7808. For
licensing issues, Dr. Paul Mele, Office of
Research and Technology Applications
(ORTA), (301) 619–6664, both at telefax
(301) 619–5034.
SUPPLEMENTARY INFORMATION: The
invention relates to materials and
methodologies for preparing multivalent
vaccines, recombinant DNA expression
E:\FR\FM\12JYN1.SGM
12JYN1
]]>Agencies
[Federal Register Volume 75, Number 132 (Monday, July 12, 2010)]
[Notices]
[Page 39667]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-16894]
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Department of the Army
Availability for Non-Exclusive or Partially Exclusive Licensing
of a U.S. Patent Application
AGENCY: Department of the Army, DoD.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Announcement is made of the availability for licensing of the
invention set forth in U.S. Patent Application Serial No. 12/149,076,
entitled ``Combinations of Gene Deletions for Live Attenuated Shigella
Vaccine Strains,'' filed April 25, 2008. Foreign rights are also
available for licensing (PCT/US2008/005342). The United States
Government, as represented by the Secretary of the Army, has rights to
this invention.
ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command,
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick,
Frederick, MD 21702-5012.
FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul
Mele, Office of Research and Technology Applications (ORTA), (301) 619-
6664, both at telefax (301) 619-5034.
SUPPLEMENTARY INFORMATION: The invention relates generally to Shigella
vaccine, strains, their use in vaccines, and the methods for treatment
of dysentery.
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2010-16894 Filed 7-9-10; 8:45 am]
BILLING CODE 3710-08-P
